175 related articles for article (PubMed ID: 11050643)
61. Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis.
Will O; Purkayastha S; Chan C; Athanasiou T; Darzi AW; Gedroyc W; Tekkis PP
Lancet Oncol; 2006 Jan; 7(1):52-60. PubMed ID: 16389184
[TBL] [Abstract][Full Text] [Related]
62. Rapid-clearance iron nanoparticles for inflammation imaging of atherosclerotic plaque: initial experience in animal model.
Sigovan M; Boussel L; Sulaiman A; Sappey-Marinier D; Alsaid H; Desbleds-Mansard C; Ibarrola D; Gamondès D; Corot C; Lancelot E; Raynaud JS; Vives V; Laclédère C; Violas X; Douek PC; Canet-Soulas E
Radiology; 2009 Aug; 252(2):401-9. PubMed ID: 19703881
[TBL] [Abstract][Full Text] [Related]
63. MR contrast in mouse lymph nodes with subcutaneous administration of iron oxide particles: size dependency.
Mori Y; Umeda M; Fukunaga M; Ogasawara K; Yoshioka Y
Magn Reson Med Sci; 2011; 10(4):219-27. PubMed ID: 22214906
[TBL] [Abstract][Full Text] [Related]
64. Dynamic signal intensity changes in liver with superparamagnetic MR contrast agents.
Reimer P; Kwong KK; Weisskoff R; Cohen MS; Brady TJ; Weissleder R
J Magn Reson Imaging; 1992; 2(2):177-81. PubMed ID: 1562768
[TBL] [Abstract][Full Text] [Related]
65. Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiography.
Bellin MF; Lebleu L; Meric JB
Abdom Imaging; 2003; 28(2):155-63. PubMed ID: 12592461
[TBL] [Abstract][Full Text] [Related]
66. Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus uspio-enhanced MR imaging.
Memarsadeghi M; Riedl CC; Kaneider A; Galid A; Rudas M; Matzek W; Helbich TH
Radiology; 2006 Nov; 241(2):367-77. PubMed ID: 17057065
[TBL] [Abstract][Full Text] [Related]
67. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging.
Montie JE
J Urol; 2005 Sep; 174(3):870-1. PubMed ID: 16093977
[No Abstract] [Full Text] [Related]
68. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study.
Anzai Y; Piccoli CW; Outwater EK; Stanford W; Bluemke DA; Nurenberg P; Saini S; Maravilla KR; Feldman DE; Schmiedl UP; Brunberg JA; Francis IR; Harms SE; Som PM; Tempany CM;
Radiology; 2003 Sep; 228(3):777-88. PubMed ID: 12954896
[TBL] [Abstract][Full Text] [Related]
69. A stable USPIO capable for MR lymphography with ultra-low effective dosage.
Nie Y; Rui Y; Miao C; Li Q; Hu F; Gu H
Nanomedicine; 2020 Oct; 29():102233. PubMed ID: 32522710
[TBL] [Abstract][Full Text] [Related]
70. Liver-directed superparamagnetic iron oxide: quantitation of T2 relaxation effects.
Pouliquen D; Lucet I; Chouly C; Perdrisot R; Le Jeune JJ; Jallet P
Magn Reson Imaging; 1993; 11(2):219-28. PubMed ID: 8455432
[TBL] [Abstract][Full Text] [Related]
71. Lymphotropic nanoparticle enhanced MR imaging (LNMRI) technique for lymph node imaging.
Saksena MA; Saokar A; Harisinghani MG
Eur J Radiol; 2006 Jun; 58(3):367-74. PubMed ID: 16472955
[TBL] [Abstract][Full Text] [Related]
72. Superparamagnetic nanoparticles as blood-pool contrast agents. Contribution to MRI preclinical investigations.
Benderbous S; Bonnemain B
Radiologe; 1995 Nov; 35(11 Suppl 2):S248-52. PubMed ID: 8588030
[No Abstract] [Full Text] [Related]
73. Contrast-enhanced sonographic imaging of lymphatic channels and sentinel lymph nodes.
Goldberg BB; Merton DA; Liu JB; Murphy G; Forsberg F
J Ultrasound Med; 2005 Jul; 24(7):953-65. PubMed ID: 15972710
[TBL] [Abstract][Full Text] [Related]
74. A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery.
Muldoon LL; Pagel MA; Kroll RA; Roman-Goldstein S; Jones RS; Neuwelt EA
AJNR Am J Neuroradiol; 1999 Feb; 20(2):217-22. PubMed ID: 10094341
[TBL] [Abstract][Full Text] [Related]
75. Magnetic iron oxide particles coated with carboxydextran for parenteral administration and liver contrasting. Pre-clinical profile of SH U555A.
Lawaczeck R; Bauer H; Frenzel T; Hasegawa M; Ito Y; Kito K; Miwa N; Tsutsui H; Vogler H; Weinmann HJ
Acta Radiol; 1997 Jul; 38(4 Pt 1):584-97. PubMed ID: 9240682
[TBL] [Abstract][Full Text] [Related]
76. Interstitial T1-weighted MR lymphography: lipophilic perfluorinated gadolinium chelates in pigs.
Staatz G; Nolte-Ernsting CC; Adam GB; Grosskortenhaus S; Misselwitz B; Bücker A; Günther RW
Radiology; 2001 Jul; 220(1):129-34. PubMed ID: 11425984
[TBL] [Abstract][Full Text] [Related]
77. MR imaging of lymph nodes in patients with primary abdominal and pelvic malignancies using ultrasmall superparamagnetic iron oxide (Combidex).
Harisinghani MG; Saini S; Hahn PF; Weissleder R; Mueller PR
Acad Radiol; 1998 Apr; 5 Suppl 1():S167-9, discussion S183-4. PubMed ID: 9561072
[No Abstract] [Full Text] [Related]
78. Pearls and pitfalls of MR lymphography in gynecologic malignancy.
Narayanan P; Iyngkaran T; Sohaib SA; Reznek RH; Rockall AG
Radiographics; 2009; 29(4):1057-69; discussion 1069-71. PubMed ID: 19605656
[TBL] [Abstract][Full Text] [Related]
79. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings--initial observations.
Koh DM; Brown G; Temple L; Raja A; Toomey P; Bett N; Norman AR; Husband JE
Radiology; 2004 Apr; 231(1):91-9. PubMed ID: 14976266
[TBL] [Abstract][Full Text] [Related]
80. Imaging of macrophages in soft-tissue infection in rats: relationship between ultrasmall superparamagnetic iron oxide dose and MR signal characteristics.
Lutz AM; Weishaupt D; Persohn E; Goepfert K; Froehlich J; Sasse B; Gottschalk J; Marincek B; Kaim AH
Radiology; 2005 Mar; 234(3):765-75. PubMed ID: 15665219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
